Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track NVCT with free AI briefings, catalyst countdowns, and dilution alerts.

NVCT · Nuvectis Pharma, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$140.7M Cash on Hand
28.3mo Cash Runway
Follow NVCT by email Get an email when NVCT reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about NVCT, unsubscribe in one click. Privacy

📣 What NVCT Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Heat Shock Factor 1 Pathway Inhibitor NXP800 Advanced Solid Tumor Phase 1 · NCT05226507 Terminated
SRC/YES1 Kinase Inhibitor NXP900 EGFR Mutation Positive Non-small Cell Lung Cancer Phase 1 · NCT07315113 Recruiting
Osimertinib EGFR Mutation Positive Non-small Cell Lung Cancer Phase 1 · NCT07315113 Recruiting

Also used in these trials (approved or third-party drugs, not NVCT's own candidates): Lorlatinib.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

NVCT holds $140.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $14.9M/quarter from operations, an estimated runway of 28.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 39 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NVCT files for a raise →

👥 Who Owns NVCT

Insiders 33.1% Other 5%+ holders 4.8% Institutions (122 holders) 32.5% Public and other holders 29.6%
HolderTypeShares% of sharesAs of
Ron Bentsur
Chairman & CEO, Director, 10% owner
Insider 3,688,424 10.73% 2026-06-30
Marlio Charles Mosseri
10% owner
Insider 3,295,897 9.58% 2026-06-30
Enrique Poradosu
Chief Science & Business Off
Insider 1,806,319 5.25% 2026-01-06
Shay Shemesh
Chief Dev. & Ops. Officer
Insider 1,793,068 5.21% 2026-01-06
Soleus Capital Management, L.P. 5%+ holder (13G) 1,648,024 4.79% 2026-08-04
Michael J. Carson
Vice President, Finance
Insider 230,118 0.67% 2026-08-03
Kenneth Hoberman
Director
Insider 168,140 0.49% 2026-06-11
Matthew L. Kaplan
Director
Insider 159,760 0.46% 2026-06-11
James F III Oliviero
Director
Insider 122,828 0.36% 2026-06-11
Juan Sanchez
Director
Insider 113,795 0.33% 2026-06-11

Share count 34,388,908 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full NVCT picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NVCT and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.